BriaCell Therapeutics Raises $13.8 Million in Public Offering to Advance Cancer Immunotherapy Research
BriaCell Therapeutics has completed a public offering of 3,066,666 units, generating approximately $13.8 million to support its clinical-stage cancer immunotherapy development efforts. The funding will help the company advance its research and corporate objectives.
